Bezafibrate 200 MG Oral Tablet ( DrugBank: Bezafibrate )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎 | 1 |
93. 原発性胆汁性胆管炎
臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04751188 (ClinicalTrials.gov) | October 2, 2020 | 5/2/2021 | A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis | Safety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without Response | Primary Biliary Cirrhosis | Drug: Bezafibrate 200 MG Oral Tablet;Drug: Placebo;Drug: Ursodeoxycholic Acid | Instituto Mexicano del Seguro Social | NULL | Active, not recruiting | 18 Years | 65 Years | All | 11 | Phase 3 | Mexico |